Eradication of Minimal Disease in Severe Combined Immunodeficient Mice With Disseminated Daudi Lymphoma Using Chemotherapy and an Immunotoxin Cocktail
نویسندگان
چکیده
Severe combined immunodeficient (SCID) mice injected intravenously with a human Burkitt’s lymphoma cell line (Daudi) develop disseminated lymphoma (SCID/Daudi), which is fatal in 100% of the mice. Early treatment of these mice with either an immunotoxin (IT) cocktail (consisting of anti-CD19-ricin A chain plus anti-CD=-ricin A chain) or chemotherapy significantly prolonged survival but was not curative. Combination therapy with the IT cocktail and any one of three chemotherapeutic drugs (doxorubicin, cytoxan,
منابع مشابه
RAPID COMMUNICATION Eradication of Minimal Disease in Severe Combined Immunodeficient Mice With Disseminated Daudi Lymphoma Using Chemotherapy and an Immunotoxin Cocktail
Severe combined immunodeficient (SCID) mice injected intravenously with a human Burkitt’s lymphoma cell line (Daudi) develop disseminated lymphoma (SCID/Daudi), which is fatal in 100% of the mice. Early treatment of these mice with either an immunotoxin (IT) cocktail (consisting of anti-CD19-ricin A chain plus anti-CD=-ricin A chain) or chemotherapy significantly prolonged survival but w...
متن کاملEradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
Severe combined immunodeficient (SCID) mice injected intravenously with a human Burkitt's lymphoma cell line (Daudi) develop disseminated lymphoma (SCID/Daudi), which is fatal in 100% of the mice. Early treatment of these mice with either an immunotoxin (IT) cocktail (consisting of anti-CD19-ricin A chain plus anti-CD22-ricin A chain) or chemotherapy significantly prolonged survival but was not...
متن کاملThe antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
The antitumor activities of immunotoxins (ITs) constructed with deglycosylated ricin A chain (dgA) and either anti-CD19 (HD37) or anti-CD22 (RFB4) monoclonal antibodies were compared in SCID mice with disseminated human Daudi lymphoma (SCID/Daudi). As reported previously, after intravenous injection with Daudi cells, SCID mice develop disseminated lymphoma, which infiltrates the vertebral colum...
متن کاملCure of Multidrug-Resistant Human B-Cell Lymphoma Xenografts by Combinations
The CD-19-directed immunotoxin anti-B4-blocked ricin (antiB4-bR) is currently in clinical trials for the treatment of Bcell malignancies. To explore the potential of using antiB4-bR with chemotherapy protocols we tested the in vivo efficacy of the immunotoxin in combination with two multidrug chemotherapeutic regimens in severe combined immunodeficient (SCID) mice bearing disseminated tumors of...
متن کاملPotent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
LL2, an anti-CD22 monoclonal antibody against B-cell lymphoma, was covalently linked to the amphibian ribonuclease, onconase, a member of the pancreatic RNase A superfamily. LL2 increased in vitro potency (10 000-fold) and specificity against human Daudi Burkitt lymphoma cells while decreasing systemic toxicity of onconase. Monensin further increased potency of LL2-onconase on Daudi cells (IC(5...
متن کامل